Dmt1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| Divalent Metal Transporter 1 | |
|---|---|
| Protein Name | Divalent Metal Transporter 1 |
| Gene | SLC11A2 |
| UniProt ID | Q8IWU6 |
| Protein Family | NRAMP (Natural Resistance-Associated Macrophage Protein) family |
| Molecular Weight | ~65 kDa (561 amino acids) |
| Subcellular Location | Endosomal membrane, Plasma membrane, Lysosomal membrane |
| Top Brain Expression | Substantia nigra, Hippocampus, Cerebral cortex |
Divalent Metal Transporter 1 (DMT1), also known as SLC11A2 or NRAMP2, is a critical membrane protein responsible for the transport of ferrous iron (Fe²⁺) and other divalent metal ions across cellular membranes. DMT1 plays a fundamental role in systemic iron homeostasis by mediating dietary iron absorption in the duodenum and facilitating iron transport across the blood-brain barrier (BBB)[1][2]. Dysregulation of DMT1 function has been strongly implicated in the pathogenesis of several neurodegenerative disorders, particularly Parkinson's disease (PD) and Alzheimer's disease (AD), where iron accumulation in specific brain regions is a hallmark feature[3].
The protein belongs to the NRAMP family of divalent metal transporters, which are conserved from bacteria to humans and function as proton-coupled metal ion symporters[4]. Understanding DMT1's role in neuronal iron homeostasis is crucial for developing therapeutic strategies targeting metal dysregulation in neurodegeneration.
DMT1 is a polytopic membrane protein with 12 predicted transmembrane domains that form a channel for metal ion transport. The protein contains:
The crystal structure of bacterial NRAMP homologs has provided insights into the transport mechanism, revealing a flexible "bucket-handle" model where metal ions are transported through a channel formed by transmembrane helices[5].
In the duodenum, DMT1 is expressed on the apical membrane of enterocytes where it absorbs dietary non-heme iron (Fe²⁺). After reduction by duodenal cytochrome B (DCYTB), Fe²⁺ is transported into the enterocyte by DMT1. This absorbed iron is either stored as ferritin or exported into the bloodstream by ferroportin (FPN), where it is oxidized to Fe³⁺ and bound to transferrin[1:1][2:1].
DMT1 is expressed on the luminal side of brain capillary endothelial cells that form the BBB. Here, it mediates the uptake of transferrin-bound iron from the bloodstream into the brain. This process involves receptor-mediated endocytosis of transferrin, followed by iron release in the endosome via acidification, and finally DMT1-mediated iron export from the endosome into the cytosol and across the BBB[6].
Within neurons and glia, DMT1 localizes to endosomes and lysosomes, facilitating iron release from these organelles. This function is critical for delivering iron to the cytosol where it is used for:
DMT1 dysregulation plays a significant role in Parkinson's disease pathogenesis:
In Alzheimer's disease, DMT1 contributes to amyloidogenesis through iron-mediated processes:
Dmt1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Dmt1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Gunshin et al., Cloning and characterization of a mammalian proton-coupled metal-ion transporter (1997) ↩︎ ↩︎
Fleming et al., A mouse model of autosomal recessive iron overload (1997) ↩︎ ↩︎
Salazar et al., Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease (2008) ↩︎ ↩︎
Klausner et al., The NRAMP family of metal-ion transporters (1995) ↩︎
Lu & Fu, Structure of the divalent metal transporter 1 in outward-open state (2017) ↩︎
Moos et al., DMT1 expression at the blood-brain barrier (2007) ↩︎
Wang et al., Increased DMT1 expression in Parkinson's disease substantia nigra (2016) ↩︎
Narskike et al., DMT1 knockout mice are resistant to MPTP neurotoxicity (2008) ↩︎
Zheng et al., DMT1 and iron homeostasis in Alzheimer's disease (2009) ↩︎
Kaur et al., Clioquinol attenuates iron-mediated neurotoxicity (2014) ↩︎